Generate Biomedicines, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|
| Revenue | $6.3M | $7.2M | $10.1M | $8.8M |
| Cost of Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Gross Margin | — | — | — | — |
| Operating Expenses | ||||
| Research & Development | $64.3M | $57.8M | $59.7M | $46.8M |
| SG&A Expense | $13.6M | $13.5M | $10.5M | $10.1M |
| Operating Income | $-71.6M | $-64.1M | $-60.2M | $-48.2M |
| Operating Margin | -1,134.2% | -887.5% | -593.8% | -546.1% |
| Interest Expense | — | — | — | — |
| Pretax Income | $-67.2M | $-61.7M | $-56.7M | $-44.3M |
| Income Tax Expense | $53.0K | $28.0K | $44.0K | $56.0K |
| Net Income | $-67.3M | $-61.4M | $-52.4M | $-41.7M |
| Net Margin | -1,065.2% | -850.6% | -517.6% | -472.7% |
| EPS (Basic) | $-0.52 | $-1.07 | $-1.94 | $-1.62 |
| EPS (Diluted) | $-0.52 | $-1.07 | $-1.94 | $-1.62 |
| Shares Outstanding (Basic) | 128.2M | 64.9M | 33.0M | 32.8M |
| Shares Outstanding (Diluted) | 128.2M | 64.9M | 33.0M | 32.8M |
| Dividends Per Share | — | — | — | — |